The administration of RAD001 in combination with CC1-779, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) chemotherapy in T-ALL or B-ALL patients inhibited the phosphorylation of S6RP, which is a downstream target of mTOR. Here, MTOR is linked to acute lymphoblastic leukemia.